Gilead Sciences (GILD) Stock: Buy, Sell, or Hold?
GILD - Gilead Sciences Inc
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 4, 2026 at $151.00 · last confirmed Sep 9, 2026
Get Alerted When GILD Hits Your Target Price
Join 10,000+ traders who never miss a move
Interactive Price Chart (1 Month)
Loading historical data...
âšī¸ NEUTRAL: GILD is fairly priced but lacks strong directional signals. At 0.5% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.3x Exit PE.
In-depth Analysis How we analyze
Technical Outlook: Technically, GILD is in a uptrend. The price is currently testing key support at $143.18. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GILD scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Protect Your Profits
Holding GILD? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (36/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($157.41)
- NEUTRAL: Market pricing in 0.5% annual earnings growth - fairly valued
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
Support & Resistance Levels
Fundamental Context
Data refreshes hourly during market hours. Next update: 11:02 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Is GILD showing a specific setup today?
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1319 | 47 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$277 | 53 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$237 | 47 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$388 | 43 HOLD |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$153 | 42 HOLD |
Advanced GILD Option Strategies
Professional options setups generated by AI based on today's GILD price and gamma walls.
